Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-71.76%)
USD 0.0
(-71.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.15 Million USD | 17.18% |
| 2022 | -39.46 Million USD | 35.12% |
| 2021 | -76.64 Million USD | -0.15% |
| 2020 | -31.8 Million USD | -40.44% |
| 2019 | -25.86 Million USD | -47.88% |
| 2018 | -18.96 Million USD | 29.69% |
| 2017 | -16.39 Million USD | 43.16% |
| 2016 | -36.71 Million USD | -0.51% |
| 2015 | -49.87 Million USD | 8.42% |
| 2014 | -38.64 Million USD | 3.07% |
| 2013 | -43.03 Million USD | -14.29% |
| 2012 | -36.15 Million USD | -36.58% |
| 2011 | -19.64 Million USD | 11.99% |
| 2010 | -17.26 Million USD | -17.19% |
| 2009 | -27.16 Million USD | 29.14% |
| 2008 | -36.17 Million USD | -1.34% |
| 2007 | -35.85 Million USD | -4.54% |
| 2006 | -43.77 Million USD | -45.35% |
| 2005 | -41.72 Million USD | 15.49% |
| 2004 | -37.09 Million USD | -22.83% |
| 2003 | -24.01 Million USD | -35.41% |
| 2002 | -17.73 Million USD | -50.87% |
| 2001 | -11.75 Million USD | 0.15% |
| 2000 | -11.77 Million USD | -134.33% |
| 1999 | -5.02 Million USD | -5125.0% |
| 1998 | -7.7 Million USD | 101.09% |
| 1997 | -6.19 Million USD | -283.33% |
| 1996 | -2.3 Million USD | -14.29% |
| 1995 | -2 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -11.42 Million USD | -212.79% |
| 2024 Q1 | -4.38 Million USD | 302.48% |
| 2023 Q2 | -4.09 Million USD | -13.89% |
| 2023 Q4 | -5.12 Million USD | -16.42% |
| 2023 FY | - USD | 17.18% |
| 2023 Q3 | -4.39 Million USD | -7.5% |
| 2023 Q1 | -3.59 Million USD | 2.71% |
| 2022 FY | - USD | 35.12% |
| 2022 Q1 | -7.64 Million USD | -2.45% |
| 2022 Q2 | -5.66 Million USD | 25.97% |
| 2022 Q3 | -3.56 Million USD | 37.0% |
| 2022 Q4 | -3.69 Million USD | -3.5% |
| 2021 Q3 | -8.15 Million USD | -3.75% |
| 2021 Q2 | -7.85 Million USD | 11.47% |
| 2021 Q1 | -8.87 Million USD | -19.8% |
| 2021 FY | - USD | -0.15% |
| 2021 Q4 | -7.46 Million USD | 8.43% |
| 2020 Q4 | -7.4 Million USD | 17.07% |
| 2020 Q1 | -6.44 Million USD | -133.62% |
| 2020 Q2 | -9.48 Million USD | -47.13% |
| 2020 FY | - USD | -40.44% |
| 2020 Q3 | -8.93 Million USD | 5.84% |
| 2019 FY | - USD | -47.88% |
| 2019 Q4 | -2.76 Million USD | 58.66% |
| 2019 Q3 | -6.67 Million USD | -11.52% |
| 2019 Q2 | -5.98 Million USD | 2.79% |
| 2019 Q1 | -6.15 Million USD | 25.23% |
| 2018 Q3 | -3.42 Million USD | -17.44% |
| 2018 FY | - USD | 29.69% |
| 2018 Q1 | -4.79 Million USD | -44.38% |
| 2018 Q2 | -2.91 Million USD | 39.12% |
| 2018 Q4 | -8.23 Million USD | -140.29% |
| 2017 Q1 | -8.05 Million USD | -19.5% |
| 2017 Q2 | -6.09 Million USD | 24.39% |
| 2017 Q4 | -3.32 Million USD | 30.01% |
| 2017 Q3 | -4.74 Million USD | 22.11% |
| 2017 FY | - USD | 43.16% |
| 2016 FY | - USD | -0.51% |
| 2016 Q4 | -6.74 Million USD | 12.11% |
| 2016 Q1 | -13.42 Million USD | -38.51% |
| 2016 Q3 | -7.67 Million USD | 22.7% |
| 2016 Q2 | -9.92 Million USD | 26.08% |
| 2015 Q1 | -10.51 Million USD | 11.02% |
| 2015 Q3 | -8.37 Million USD | 18.67% |
| 2015 Q2 | -10.3 Million USD | 2.04% |
| 2015 Q4 | -9.69 Million USD | -15.71% |
| 2015 FY | - USD | 8.42% |
| 2014 Q4 | -11.81 Million USD | -26.66% |
| 2014 Q1 | -10.05 Million USD | -14.19% |
| 2014 Q3 | -9.33 Million USD | 17.15% |
| 2014 Q2 | -11.26 Million USD | -12.05% |
| 2014 FY | - USD | 3.07% |
| 2013 Q2 | -10.64 Million USD | 14.33% |
| 2013 Q4 | -8.8 Million USD | 8.14% |
| 2013 Q3 | -9.58 Million USD | 9.97% |
| 2013 Q1 | -12.42 Million USD | 31.12% |
| 2013 FY | - USD | -14.29% |
| 2012 Q3 | -6.65 Million USD | 36.63% |
| 2012 Q4 | -18.03 Million USD | -171.2% |
| 2012 Q2 | -10.49 Million USD | -233.78% |
| 2012 FY | - USD | -36.58% |
| 2012 Q1 | -3.14 Million USD | 56.49% |
| 2011 Q2 | -4.68 Million USD | 43.44% |
| 2011 Q4 | -7.22 Million USD | 4.78% |
| 2011 FY | - USD | 11.99% |
| 2011 Q3 | -7.58 Million USD | -62.02% |
| 2011 Q1 | -8.28 Million USD | 31.66% |
| 2010 FY | - USD | -17.19% |
| 2010 Q1 | -6.84 Million USD | -26.38% |
| 2010 Q2 | -6.14 Million USD | 10.2% |
| 2010 Q4 | -12.11 Million USD | -106.95% |
| 2010 Q3 | -5.85 Million USD | 4.7% |
| 2009 Q1 | -8.18 Million USD | -5.48% |
| 2009 Q3 | -6.7 Million USD | 9.17% |
| 2009 FY | - USD | 29.14% |
| 2009 Q2 | -7.38 Million USD | 9.86% |
| 2009 Q4 | -5.41 Million USD | 19.23% |
| 2008 FY | - USD | -1.34% |
| 2008 Q3 | -9.85 Million USD | -4.31% |
| 2008 Q4 | -7.76 Million USD | 21.24% |
| 2008 Q2 | -9.44 Million USD | -3.66% |
| 2008 Q1 | -9.11 Million USD | 19.57% |
| 2007 Q3 | -8.9 Million USD | 9.68% |
| 2007 Q2 | -9.85 Million USD | -26.33% |
| 2007 Q1 | -7.8 Million USD | -3.01% |
| 2007 FY | - USD | -4.54% |
| 2007 Q4 | -11.33 Million USD | -27.31% |
| 2006 Q3 | -7.69 Million USD | -57.03% |
| 2006 FY | - USD | -45.35% |
| 2006 Q4 | -7.57 Million USD | 1.53% |
| 2006 Q1 | -16.08 Million USD | -27.94% |
| 2006 Q2 | -4.89 Million USD | 69.55% |
| 2005 FY | - USD | 15.49% |
| 2005 Q2 | -9.76 Million USD | -7.14% |
| 2005 Q1 | -9.11 Million USD | 22.71% |
| 2005 Q3 | -10.27 Million USD | -5.17% |
| 2005 Q4 | -12.56 Million USD | -22.36% |
| 2004 Q2 | -8.85 Million USD | -0.01% |
| 2004 Q4 | -11.79 Million USD | -45.3% |
| 2004 Q3 | -8.11 Million USD | 8.28% |
| 2004 FY | - USD | -22.83% |
| 2004 Q1 | -8.84 Million USD | -10.95% |
| 2003 FY | - USD | -35.41% |
| 2003 Q3 | -6.27 Million USD | -35.99% |
| 2003 Q2 | -4.61 Million USD | 0.11% |
| 2003 Q1 | -4.61 Million USD | -4.39% |
| 2003 Q4 | -7.97 Million USD | -27.15% |
| 2002 Q2 | -4.15 Million USD | -18.71% |
| 2002 Q1 | -3.5 Million USD | 19.87% |
| 2002 Q3 | -4.74 Million USD | -14.08% |
| 2002 Q4 | -4.42 Million USD | 6.67% |
| 2002 FY | - USD | -50.87% |
| 2001 Q1 | -2.36 Million USD | 70.54% |
| 2001 Q4 | -4.36 Million USD | -82.3% |
| 2001 FY | - USD | 0.15% |
| 2001 Q3 | -2.45 Million USD | -1.78% |
| 2001 Q2 | -2.77 Million USD | -17.0% |
| 2000 Q4 | -6.82 Million USD | -863.19% |
| 2000 Q3 | -1.63 Million USD | 41.65% |
| 2000 Q2 | -2.18 Million USD | 15.86% |
| 2000 Q1 | -1.44 Million USD | -8.98% |
| 2000 FY | - USD | -134.33% |
| 1999 Q1 | -1.96 Million USD | 24.0% |
| 1999 Q4 | -1.32 Million USD | -120.83% |
| 1999 Q3 | -600 Thousand USD | 45.45% |
| 1999 FY | - USD | -5125.0% |
| 1999 Q2 | -1.19 Million USD | 42.11% |
| 1998 Q4 | -2.5 Million USD | -108.33% |
| 1998 Q3 | -1.2 Million USD | -120.34% |
| 1998 Q2 | 5.9 Million USD | 368.18% |
| 1998 Q1 | -2.2 Million USD | 71.79% |
| 1998 FY | - USD | 101.09% |
| 1997 Q2 | -2.2 Million USD | 33.33% |
| 1997 Q1 | -600 Thousand USD | 25.0% |
| 1997 Q3 | -100 Thousand USD | 75.0% |
| 1997 FY | - USD | -283.33% |
| 1997 Q4 | -7.8 Million USD | -7700.0% |
| 1996 Q4 | -800 Thousand USD | -14.29% |
| 1996 Q3 | -700 Thousand USD | -133.33% |
| 1996 Q2 | -300 Thousand USD | 25.0% |
| 1996 FY | - USD | -14.29% |
| 1996 Q1 | -400 Thousand USD | 84.0% |
| 1995 Q4 | -2.5 Million USD | -2600.0% |
| 1995 Q2 | -900 Thousand USD | -200.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q3 | 100 Thousand USD | 111.11% |
| 1995 Q1 | -300 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 71.621% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -240.012% |
| SQZ Biotechnologies Company | -64.14 Million USD | 68.571% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -16.056% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 121.437% |
| Mesoblast Limited | -62.38 Million USD | 67.689% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1212.393% |
| Genus plc | 73.7 Million USD | 127.353% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -204.907% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -468.34% |
| Marizyme, Inc. | -34.28 Million USD | 41.196% |
| ContraFect Corporation | -64.99 Million USD | 68.986% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -129.811% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -345.385% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1338.071% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -662.314% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -767.494% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3791.353% |
| Accustem Sciences Inc. | -3.74 Million USD | -438.087% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 58.2% |
| EV Biologics, Inc. | -1.26 Million USD | -1490.916% |
| Q BioMed Inc. | -617.62 Thousand USD | -3163.939% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 664.362% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3087.667% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -782.429% |
| Biomind Labs Inc. | -1.03 Million USD | -1848.579% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 304.1% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -181.5% |
| Skye Bioscience, Inc. | -13.54 Million USD | -48.802% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1255.307% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -80536.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -418.984% |
| IMV Inc. | -35.52 Million USD | 43.251% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -27.028% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -705.728% |
| GB Sciences, Inc. | -1.41 Million USD | -1319.763% |
| Alpha Cognition Inc. | -9.7 Million USD | -107.705% |
| HST Global, Inc. | -5303.00 USD | -380043.315% |
| CSL Limited | 4.78 Billion USD | 100.421% |
| Halberd Corporation | -74.27 Thousand USD | -27039.568% |
| Enzolytics Inc. | -2.12 Million USD | -849.987% |
| Resverlogix Corp. | -11.74 Million USD | -71.683% |
| Affymax, Inc. | -14.29 Million USD | -41.021% |
| SYBLEU INC | -141.57 Thousand USD | -14139.498% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -558.142% |
| argenx SE | -216.02 Million USD | 90.668% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 63.572% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1756.45% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1244.914% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 5421.188% |
| AVAX Technologies, Inc. | -6.11 Million USD | -229.792% |
| Zenith Capital Corp. | -8.6 Million USD | -134.244% |
| Genscript Biotech Corporation | -248.71 Million USD | 91.895% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -115616.664% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -724.007% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -11352.392% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 49.141% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -596.982% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1826.672% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 299906.663% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1051.944% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -949.45% |
| BioStem Technologies, Inc. | -7.55 Million USD | -166.878% |
| ONE Bio Corp. | 13.61 Million USD | 248.086% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -11032.157% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -880.019% |
| Agentix Corp. | -1.37 Million USD | -1369.576% |
| LadRx Corporation | 412.28 Thousand USD | 4989.603% |
| Cell Source, Inc. | -4.27 Million USD | -371.829% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -5389.61% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1475.144% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -2051.558% |
| NovAccess Global Inc. | -1.03 Million USD | -1848.112% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 327.688% |
| Itoco Inc. | -1.86 Million USD | -978.601% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -5210.31% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1706.362% |
| Kadimastem Ltd | -2.62 Million USD | -668.143% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -8329.438% |
| CytoDyn Inc. | -18.02 Million USD | -11.814% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -25408.358% |
| Mobile Lads Corp. | -2.24 Million USD | -799.49% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -164745.858% |
| Qrons Inc. | -40.08 Thousand USD | -50195.651% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -4050.692% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3922.097% |
| Rebus Holdings, Inc. | -951 Thousand USD | -2019.769% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1798.193% |
| International Stem Cell Corporation | 202 Thousand USD | 10079.703% |
| Bioxytran, Inc. | -3.82 Million USD | -427.702% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -38195.973% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -718.828% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 43.798% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -44697.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -636.267% |
| Neutra Corp. | -181.24 Thousand USD | -11022.391% |
| PureTech Health plc | -11.62 Million USD | -73.381% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -0.007% |
| IXICO plc | -707 Thousand USD | -2751.344% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -162.316% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 58.303% |
| CSL Limited | 4.73 Billion USD | 100.426% |
| Cellectis S.A. | -92.63 Million USD | 78.238% |